Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cytochrome P450, family 1, subfamily A, polypeptide 2 | Starlite/ChEMBL | References |
Homo sapiens | prostaglandin D2 receptor 2 | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 2, subfamily D, polypeptide 6 | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 3, subfamily A, polypeptide 4 | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 2, subfamily B, polypeptide 6 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | cytochrome P450 | cytochrome P450, family 3, subfamily A, polypeptide 4 | 502 aa | 492 aa | 24.2 % |
Mycobacterium tuberculosis | Probable cytochrome P450 136 Cyp136 | cytochrome P450, family 2, subfamily B, polypeptide 6 | 491 aa | 395 aa | 19.5 % |
Brugia malayi | cytochrome P450 | cytochrome P450, family 2, subfamily D, polypeptide 6 | 497 aa | 425 aa | 32.0 % |
Brugia malayi | Cytochrome P450 family protein | cytochrome P450, family 1, subfamily A, polypeptide 2 | 516 aa | 470 aa | 26.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | membrane-associated oxidoreductase | 0.0196 | 1 | 1 |
Mycobacterium leprae | possibleputative FAD-linked oxidoreductase | 0.0196 | 1 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0196 | 1 | 0.5 |
Schistosoma mansoni | monoxygenase | 0.0196 | 1 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0196 | 1 | 0.5 |
Mycobacterium ulcerans | oxidoreductase | 0.0196 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0196 | 1 | 1 |
Mycobacterium ulcerans | oxidoreductase GMC-type | 0.0196 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0196 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0196 | 1 | 1 |
Echinococcus multilocularis | protein MICAL 3 | 0.0196 | 1 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0196 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0196 | 1 | 1 |
Trypanosoma cruzi | Monooxygenase, putative | 0.0196 | 1 | 1 |
Echinococcus granulosus | protein MICAL 3 | 0.0196 | 1 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0196 | 1 | 1 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0196 | 1 | 0.5 |
Mycobacterium ulcerans | FAD-linked oxidoreductase | 0.0196 | 1 | 1 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0196 | 1 | 0.5 |
Plasmodium vivax | FAD-dependent monooxygenase, putative | 0.0196 | 1 | 0.5 |
Echinococcus granulosus | ubiquinone biosynthesis monooxygenase COQ6 | 0.0196 | 1 | 0.5 |
Mycobacterium ulcerans | oxidoreductase | 0.0196 | 1 | 1 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0196 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 2-polyprenyl-6-methoxyphenol 4-hydroxylase | 0.0196 | 1 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0196 | 1 | 1 |
Echinococcus multilocularis | ubiquinone biosynthesis monooxygenase COQ6 | 0.0196 | 1 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0196 | 1 | 0.5 |
Trypanosoma brucei | kynurenine 3-monooxygenase, putative | 0.0196 | 1 | 1 |
Plasmodium falciparum | FAD-dependent monooxygenase, putative | 0.0196 | 1 | 0.5 |
Trypanosoma brucei | Monooxygenase, putative | 0.0196 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0196 | 1 | 0.5 |
Brugia malayi | Cytochrome P450 family protein | 0.004 | 0.0741 | 1 |
Mycobacterium ulcerans | FAD-dependent oxidoreductase | 0.0196 | 1 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0196 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0196 | 1 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.004 | 0.0741 | 0.0741 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (ADMET) | > 10 uM | Inhibition of human recombinant CYP1A2 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry | ChEMBL. | 24900284 |
IC50 (ADMET) | > 10 uM | Inhibition of human recombinant CYP2B6 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry | ChEMBL. | 24900284 |
IC50 (ADMET) | > 10 uM | Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry | ChEMBL. | 24900284 |
IC50 (ADMET) | > 10 uM | Inhibition of human recombinant CYP2D6 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry | ChEMBL. | 24900284 |
Ki (binding) | = 4.5 nM | Displacement of [3HPGD2 from human CRTH2 receptor expressed in CHO cell membrane after 90 mins by scintillation proximity assay | ChEMBL. | 24900284 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.